Project Grant R21OD039840
- Federal Grant Award Summary Cornell University received a $125,000 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), awarded May 1, 2026, with completion scheduled for April 30, 2028. The research project, conducted at Cornell's Ithaca, New York facility, focuses on developing innovative methodologies to comprehensively measure inter-organelle phospholipid transport in living cells. The primary...
- Federal Grant Award Summary Cornell University received a $399,750 Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Research Infrastructure Programs (CFDA 93.351) to acquire a LifeCanvas Technologies SmartSPIM lightsheet microscope for the Cornell Biotechnology Resource Center (BRC) Imaging Facility. The award, dated May 15, 2026, with completion by May 14, 2027, supports the purchase and installation of this advanced microscopy system at the...
- Federal Grant Award Summary Cornell University received a $404,864 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective May 22, 2026, through March 31, 2031. The award supports research investigating quantitative membrane contact site biology in autophagy, specifically focusing on the mechanistic and quantitative understanding of autophagosome biogenesis—the cellular process by...
- Federal Grant Award Summary Cornell University's Office of Sponsored Programs received a $375,154 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective June 1, 2026, through February 28, 2031. The award supports a five-year research initiative to uncover the structure and function of understudied membrane proteins implicated in human diseases. Using Caenorhabditis elegans as a model...
- Federal Grant Award Summary Cornell University received a $750,000 project grant from the National Institutes of Health (NIH) Office of the Director under the Research Infrastructure Programs (CFDA 93.351) to acquire an Orbitrap Astral mass spectrometer system interfaced with a Vanquish Neo ultra-high-performance liquid chromatography system from Thermo Fisher Scientific. The award, effective July 1, 2026 through June 30, 2027, supports the installation and operational setup of this...
- Federal Grant Award Summary Cornell University received a $431,750 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective March 1, 2026 through February 28, 2031. The award supports fundamental research investigating the drivers of convergent molecular evolution during biological adaptation, with a specific focus on understanding how genetic constraints and epistatic interactions shape...
- Federal Grant Award Summary Award Details: Cornell University's Office of Sponsored Programs received a $305,208 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective August 1, 2025, through July 31, 2030. The award supports fundamental research into ubiquitin mechanisms in cellular health and pathogen-host interactions, a critical area of investigation given ubiquitination's central role...
- Federal Project Grant Award Summary Cornell University received a $380,785 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), awarded September 15, 2025, with completion targeted for August 31, 2030. The award supports research on quantitative recovery of biomolecular structural ensembles from cryo-electron microscopy (cryo-EM), a technique that captures protein conformational states by...
- Federal Project Grant Award Summary Cornell University received a $196,250 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), with an award date of May 6, 2026 and completion date of April 30, 2028. The award funds research investigating hierarchical control mechanisms in an endocrine-mediated gene regulatory network that supports innate immunity. The research focuses on the hormone...
- Federal Project Grant Award Summary Cornell University's Office of Sponsored Programs received a $797,010 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective August 1, 2025, with a completion date of May 31, 2030. The award funds research to establish culture conditions for previously uncultured microorganisms, enabling their isolation and study in controlled laboratory environments....
Cornell University received a $432,204 Project Grant from the National Institutes of Health (NIH) Office of the Director under the Research Infrastructure Programs (CFDA 93.351) for the period July 1, 2026 through June 30, 2028. The award supports the development of a novel tissue-specific protein labeling technique in Drosophila disease models. The project will establish split-intein HaloTag (SIH) tools that enable researchers to label endogenous proteins with cell-type specificity in living tissues, addressing current limitations in protein characterization methods that lack adequate signal intensity or tissue selectivity for live imaging applications. The research deliverables consist of two primary objectives: (1) development and validation of SIH tools for tissue-specific protein labeling across diverse cellular compartments and body systems in Drosophila, including establishment of in vivo and ex vivo labeling protocols and determination of sensitivity and kinetics parameters; and (2) application of the SIH method to examine dynamics of disease-related endogenous proteins in disease models, particularly low-abundance membrane transporters such as ATP8A. This research infrastructure initiative will generate methodological advances applicable to studying protein abnormalities underlying cancers, neurodegenerative diseases, cardiovascular diseases, metabolic disorders, and immunological diseases.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $432.2k | 6/19/26 |